Areef Ishani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Areef Ishani has a total of 141 co-authors. Here are the top co-authors by number of shared publications:
- Cynthia Hau
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, MA 02111, USA
6 shared publications - Sarah M. Leatherman
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System, Boston, Massachusetts
6 shared publications Ryan E. Ferguson
Cooperative Studies Program Coordinating Center, VA Boston Healthcare System
4 shared publications- William C. Cushman
Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis (W.C.C.).
4 shared publications Addison A. Taylor
Michael E. DeBakey VA Medical Center , Houston , TX , USA
3 shared publications- Paul Englund Drawz
Division of Renal Diseases and Hypertension, University of Minnesota Medical School, Minneapolis, Minnesota
3 shared publications
Latest Publications
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
β-Blockers in Hemodialysis Outcome Trial
Was not provided for this article.
- 12 October 2026
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
β-Blockers in Hemodialysis Outcome Trial
Was not provided for this article.
- 13 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1307-1309
Twenty Years of CKD Surveillance
Was not provided for this article.
- 13 July 2026
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (8) , 1307-1309
Twenty Years of CKD Surveillance
Was not provided for this article.
- Open Access
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2613081
Pharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve clinical outcomes for patients with type 2 diabetes and chronic kidney disease (CKD), yet their uptake in clinical practice remains low. Objective: To assess whether pharmacist-led outreach would be associated with increased initiation of SGLT2 inhibitor use among patients with type 2 diabetes and CKD. Design, Setting, and Participants: In this quality improvement study, eligible patients identified through an established Veterans Affairs (VA) diabetes dashboard were divided into 2 groups based on the last digit of their Social Security number, creating a pseudorandomized treatment assignment. The study was conducted from February 2022 through April 2024 in 8 VA health systems in the midwestern US. Veterans with CKD (estimated glomerular filtration rate ≥25 and 2 ) and type 2 diabetes were included. Patients were excluded if they were already prescribed an SGLT2 inhibitor or had an SGLT2 inhibitor allergy, type 1 diabetes, or contraindicating conditions. Intervention: Eligible patients in the intervention group were mailed a letter describing the benefits of SGLT2 inhibitors. Patients were then scheduled for a 30-minute telephone visit with a pharmacist. Patients determined to be a candidate for the medication were prescribed empagliflozin. The usual care group received no targeted outreach but could be prescribed the medication during the natural course of care. Main Outcomes and Measures: The primary outcome was initiation of an SGLT2 inhibitor, determined by prescription fill, at any point during the study. The secondary outcome was SGLT2 inhibitor prescription fill at 12 months. The exploratory outcomes, assessed by win ratio analysis, included a composite of time to all-cause mortality, kidney failure, heart failure, myocardial infarction, and stroke along with each of these outcomes individually. Longer time to event for the intervention than the control group was considered a win. Results: Of 8658 eligible patients (mean [SD] age, 78.7 [8.1] years; 8368 [96.7%] male; 76 [0.9%] American Indian or Alaska Native, 11 [0.1%] Asian, 327 [3.8%] Black, 44 [0.5%] Pacific Islander, 7435 [85.9%] White, and 765 [8.8%] with unknown or unreported race), 4400 (50.8%) were assigned to the pharmacist intervention and 4258 (49.2%) to usual care. The cumulative proportion of SGLT2 inhibitor prescriptions filled 1 year after group assignment was 1476 (33.5%) for the intervention group compared with 659 (15.5%) for control. At 12 months, 864 intervention patients (19.6%) filled a prescription for an SGLT2 inhibitor compared with 415 (9.7%) in the control group. The hazard ratio for initiation of an SGLT2 inhibitor in the intervention vs control group was 1.91 (95% CI, 1.69-2.16; P < .001). No significant difference was observed in the composite clinical outcome (win ratio, 1.02; 95% CI, 0.97-1.07; P = .54). Conclusions and Relevance: In this quality improvement study, pharmacist-led outreach was associated with increased initiation of SGLT2 inhibitors; however, limited intervention reach may have constrained the overall impact. Strategies to improve uptake are needed to enhance impact and inform broader SGLT2 inhibitor implementation in patients with CKD and type 2 diabetes.
- 1 May 2026
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 9 (5) , e2613081
Open AccessPharmacist Outreach and SGLT2 Inhibitor Uptake in Patients With Diabetes and Chronic Kidney Disease
Importance: Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been shown to improve clinical outcomes for patients with type 2 diabetes and chronic kidney disease (CKD), yet their uptake in clinical practice remains low. Objective: To assess whether pharmacist-led outreach would be associated with increased initiation of SGLT2 inhibitor use among patients with type 2 diabetes and CKD. Design, Setting, and Participants: In this quality improvement study, eligible patients identified through an established Veterans Affairs (VA) diabetes dashboard were divided into 2 groups based on the last digit of their Social Security number, creating a pseudorandomized treatment assignment. The study was conducted from February 2022 through April 2024 in 8 VA health systems in the midwestern US. Veterans with CKD (estimated glomerular filtration rate ≥25 and 2 ) and type 2 diabetes were included. Patients were excluded if they were already prescribed an SGLT2 inhibitor or had an SGLT2 inhibitor allergy, type 1 diabetes, or contraindicating conditions. Intervention: Eligible patients in the intervention group were mailed a letter describing the benefits of SGLT2 inhibitors. Patients were then scheduled for a 30-minute telephone visit with a pharmacist. Patients determined to be a candidate for the medication were prescribed empagliflozin. The usual care group received no targeted outreach but could be prescribed the medication during the natural course of care. Main Outcomes and Measures: The primary outcome was initiation of an SGLT2 inhibitor, determined by prescription fill, at any point during the study. The secondary outcome was SGLT2 inhibitor prescription fill at 12 months. The exploratory outcomes, assessed by win ratio analysis, included a composite of time to all-cause mortality, kidney failure, heart failure, myocardial infarction, and stroke along with each of these outcomes individually. Longer time to event for the intervention than the control group was considered a win. Results: Of 8658 eligible patients (mean [SD] age, 78.7 [8.1] years; 8368 [96.7%] male; 76 [0.9%] American Indian or Alaska Native, 11 [0.1%] Asian, 327 [3.8%] Black, 44 [0.5%] Pacific Islander, 7435 [85.9%] White, and 765 [8.8%] with unknown or unreported race), 4400 (50.8%) were assigned to the pharmacist intervention and 4258 (49.2%) to usual care. The cumulative proportion of SGLT2 inhibitor prescriptions filled 1 year after group assignment was 1476 (33.5%) for the intervention group compared with 659 (15.5%) for control. At 12 months, 864 intervention patients (19.6%) filled a prescription for an SGLT2 inhibitor compared with 415 (9.7%) in the control group. The hazard ratio for initiation of an SGLT2 inhibitor in the intervention vs control group was 1.91 (95% CI, 1.69-2.16; P < .001). No significant difference was observed in the composite clinical outcome (win ratio, 1.02; 95% CI, 0.97-1.07; P = .54). Conclusions and Relevance: In this quality improvement study, pharmacist-led outreach was associated with increased initiation of SGLT2 inhibitors; however, limited intervention reach may have constrained the overall impact. Strategies to improve uptake are needed to enhance impact and inform broader SGLT2 inhibitor implementation in patients with CKD and type 2 diabetes.
- Open Access
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e046142
Per‐Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention—Diuretic Comparison Project
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.
- 30 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (3) , e046142
Open AccessPer‐Protocol Analysis of Chlorthalidone Versus Hydrochlorothiazide for Cardiovascular Event Prevention—Diuretic Comparison Project
Background: The DCP (Diuretic Comparison Project), a pragmatic trial, evaluated whether chlorthalidone compared with hydrochlorothiazide would reduce the risk of nonfatal cardiovascular disease or noncancer‐related death. The intent‐to‐treat analysis found no difference in such comparison (hazard ratio, 1.04 [95% CI, 0.94–1.16]). The objective of the current study is to estimate the per‐protocol effect of chlorthalidone (12.5/25 mg daily) compared with hydrochlorothiazide (25/50 mg daily) in preventing major adverse cardiovascular events among older patients with hypertension. Methods: The effect of adhering to treatment strategies was assessed by censoring at first instance of nonadherence, defined as a gap (>90‐day gap in drug coverage), switch (switching between study medications), and discontinuation (stop taking chlorthalidone/hydrochlorothiazide altogether for >90 days before the end of the study). The primary outcome was a composite of nonfatal myocardial infarction, stroke, heart failure resulting in hospitalization, urgent coronary revascularization for unstable angina, and noncancer‐related death. Using inverse probability weighting, we evaluated the per‐protocol effect of chlorthalidone and hydrochlorothiazide using DCP trial data. Results: Nonadherence was found in 5476 (40%) participants; among 8047 (60%) adherents, 3905 (49%) were randomized to chlorthalidone and 4142 (51%) to hydrochlorothiazide. After censoring time when participants deviated from the assigned treatments, the estimated 5‐year risk ratio of the composite primary outcome of nonfatal cardiovascular disease and noncancer‐related death was 1.36 (95% CI, 0.96–2.12) in chlorthalidone compared with hydrochlorothiazide. Conclusions: The per‐protocol analysis indicated a lower risk with hydrochlorothiazide compared with chlorthalidone in preventing nonfatal cardiovascular disease and noncancer‐related death; however, this difference was not statistically significant using dispensation data to identify adherence. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02185417.
- Open Access
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Developing and evaluating per-protocol adherence definitions in a large pragmatic clinical trial: insights from the Diuretic Comparison Project
Objectives: Pragmatic clinical trials leveraging real-world data, such as the Diuretic Comparison Project (DCP), present unique challenges in measuring treatment adherence compared to traditional randomized controlled trials. In DCP, medications were managed through routine VA care and monitored via pharmacy claims, requiring tailored methods to assess adherence beyond standard measures like medication possession ratio (MPR). To develop a data-driven approach to define protocol treatment adherence for pragmatic comparative effectiveness trials. Methods: Structured EHR pharmacy dispense records guided categorization of treatment changes for two diuretics – chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). We examined fill intervals, total drug supply, filling patterns among others to identify prescribing characteristics informing medication adherence definitions and time censoring for per-protocol analysis. Results: Nonadherence was defined as having a gap (>90-days pause in assigned treatment), switch (receiving the other study medication), or discontinuation (without CTD/HCTZ for >90-days). 5,476 patients met nonadherence criteria – 2,851 (52 %) in CTD and 2,625 (48 %) in HCTZ. Switching occurred earlier in CTD patients, gaps were more common in HCTZ, but discontinuation was similar between groups. Conclusions: Defining adherence requires complex decision-making hybrid framework entailing both clinical and statistical expertise. Pragmatic studies should allow flexibility to generate data-driven, clinically-sensitive measures that appropriately describe trial compliance.
- 1 January 2026
- Published by Walter de Gruyter GmbH in Open Medicine
- Vol. 21 (1)
Open AccessDeveloping and evaluating per-protocol adherence definitions in a large pragmatic clinical trial: insights from the Diuretic Comparison Project
Objectives: Pragmatic clinical trials leveraging real-world data, such as the Diuretic Comparison Project (DCP), present unique challenges in measuring treatment adherence compared to traditional randomized controlled trials. In DCP, medications were managed through routine VA care and monitored via pharmacy claims, requiring tailored methods to assess adherence beyond standard measures like medication possession ratio (MPR). To develop a data-driven approach to define protocol treatment adherence for pragmatic comparative effectiveness trials. Methods: Structured EHR pharmacy dispense records guided categorization of treatment changes for two diuretics – chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). We examined fill intervals, total drug supply, filling patterns among others to identify prescribing characteristics informing medication adherence definitions and time censoring for per-protocol analysis. Results: Nonadherence was defined as having a gap (>90-days pause in assigned treatment), switch (receiving the other study medication), or discontinuation (without CTD/HCTZ for >90-days). 5,476 patients met nonadherence criteria – 2,851 (52 %) in CTD and 2,625 (48 %) in HCTZ. Switching occurred earlier in CTD patients, gaps were more common in HCTZ, but discontinuation was similar between groups. Conclusions: Defining adherence requires complex decision-making hybrid framework entailing both clinical and statistical expertise. Pragmatic studies should allow flexibility to generate data-driven, clinically-sensitive measures that appropriately describe trial compliance.
- Open Access
- 9 December 2025
- Published by MDPI AG in Diabetology
- Vol. 6 (12) , 161
Glucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes
Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) differ by estimated glomerular filtration rate (eGFR). To address this question and in the absence of definitive randomized controlled trials, we performed a retrospective observational study of US Veterans with T2DM to evaluate mortality hazard ratios associated with GLP-1 RA use at different eGFR levels. Methods: This administrative claims-based cohort included 1,188,052 U.S. Veterans with T2DM as of 1 January 2020. Initiation of GLP-1 RA was treated as a time-dependent variable and vital status of Veterans was followed until 31 December 2023. Results: A total of 31,676 Veterans met inclusion criteria. Over the study timeframe, 6.1% initiated treatment with GLP-1 RA and 57.7% died. Older age and eGFR < 15 mL/min/1.73 m2 were associated with a decreased likelihood of GLP-1 RA initiation. In contrast, younger age and lower comorbidity burden were associated with decreased mortality, a finding that persisted even after adjustment for several baseline covariates. Conclusions: Among those with T2DM and eGFR < 25 mL/min/1.73 m2, initiation of GLP-1 RA was associated with improved survival. This association remained significant with decreasing levels of kidney function, as well as among those receiving kidney replacement therapy (KRT). In conclusion, longer survival was observed both in participants on KRT and in those with eGFR 15–24 mL/min/1.73 m2 not on KRT, but these findings were not observed among those with eGFR ≤ 15 mL/min/1.73 m2.
- 9 December 2025
- Published by MDPI AG in Diabetology
- Vol. 6 (12) , 161
Open AccessGlucagon-like Peptide-1 Receptor Agonists and Survival in Advanced Chronic Kidney Disease and Type 2 Diabetes
Background/Objectives: In populations with type 2 diabetes mellitus (T2DM), it is unknown whether the survival benefits of glucagon-like peptide-1 receptor agonists (GLP-1 RA) differ by estimated glomerular filtration rate (eGFR). To address this question and in the absence of definitive randomized controlled trials, we performed a retrospective observational study of US Veterans with T2DM to evaluate mortality hazard ratios associated with GLP-1 RA use at different eGFR levels. Methods: This administrative claims-based cohort included 1,188,052 U.S. Veterans with T2DM as of 1 January 2020. Initiation of GLP-1 RA was treated as a time-dependent variable and vital status of Veterans was followed until 31 December 2023. Results: A total of 31,676 Veterans met inclusion criteria. Over the study timeframe, 6.1% initiated treatment with GLP-1 RA and 57.7% died. Older age and eGFR < 15 mL/min/1.73 m2 were associated with a decreased likelihood of GLP-1 RA initiation. In contrast, younger age and lower comorbidity burden were associated with decreased mortality, a finding that persisted even after adjustment for several baseline covariates. Conclusions: Among those with T2DM and eGFR < 25 mL/min/1.73 m2, initiation of GLP-1 RA was associated with improved survival. This association remained significant with decreasing levels of kidney function, as well as among those receiving kidney replacement therapy (KRT). In conclusion, longer survival was observed both in participants on KRT and in those with eGFR 15–24 mL/min/1.73 m2 not on KRT, but these findings were not observed among those with eGFR ≤ 15 mL/min/1.73 m2.
- Open Access
- 27 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2710
Social Determinants of Health ICD-10 Code Use by a Large Integrated Healthcare System
Background/Objectives: Identifying social determinants of health (SDOH) is important for effective clinical care. The ICD-10 introduced diagnostic categories to describe patients’ adverse SDOH, but these codes are infrequently used across health systems, presenting challenges to implement data-driven healthcare. This study illustrates SDOH code utilization within a setting that is recognized as one of the largest integrated healthcare systems across the United States. Methods: Real-world clinical data were used with ICD-10 SDOH records obtained from 13,523 participants randomized into the Diuretic Comparison Project, a pragmatic trial conducted within the Veterans Affairs (VA) Health Care System between 2016 and 2022. SDOH code utilization was assessed across study years and among the specialized outpatient clinics. Results: A total of 29,305 SDOH records were identified, and 99.2% were from outpatient encounters. Social, mental, and housing care services generated the most SDOH records. Moreover, 3894 (28.8%) participants had at least one SDOH record during the 6-year period. Particular, 6.9% of participants had a record in the first year, and this increased to 7.6%, 8.1%, 8.7%, 9.6%, 10.3% in consecutive years. Conclusions: Our results suggest that SDOH code utilization has continued to improve within the VA, but SDOH assessments may not occur annually or be performed systematically within an integrated health setting. Much work is needed to develop universal screening tools and mandate routine SDOH evaluations. Nevertheless, a persistent increase in the counts of ICD-10 SDOH records shows a positive movement towards systematic documentation, supporting service providers to efficiently identify patients with adverse SDOH.
- 27 October 2025
- Published by MDPI AG in Healthcare
- Vol. 13 (21) , 2710
Open AccessSocial Determinants of Health ICD-10 Code Use by a Large Integrated Healthcare System
Background/Objectives: Identifying social determinants of health (SDOH) is important for effective clinical care. The ICD-10 introduced diagnostic categories to describe patients’ adverse SDOH, but these codes are infrequently used across health systems, presenting challenges to implement data-driven healthcare. This study illustrates SDOH code utilization within a setting that is recognized as one of the largest integrated healthcare systems across the United States. Methods: Real-world clinical data were used with ICD-10 SDOH records obtained from 13,523 participants randomized into the Diuretic Comparison Project, a pragmatic trial conducted within the Veterans Affairs (VA) Health Care System between 2016 and 2022. SDOH code utilization was assessed across study years and among the specialized outpatient clinics. Results: A total of 29,305 SDOH records were identified, and 99.2% were from outpatient encounters. Social, mental, and housing care services generated the most SDOH records. Moreover, 3894 (28.8%) participants had at least one SDOH record during the 6-year period. Particular, 6.9% of participants had a record in the first year, and this increased to 7.6%, 8.1%, 8.7%, 9.6%, 10.3% in consecutive years. Conclusions: Our results suggest that SDOH code utilization has continued to improve within the VA, but SDOH assessments may not occur annually or be performed systematically within an integrated health setting. Much work is needed to develop universal screening tools and mandate routine SDOH evaluations. Nevertheless, a persistent increase in the counts of ICD-10 SDOH records shows a positive movement towards systematic documentation, supporting service providers to efficiently identify patients with adverse SDOH.
- Open Access
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5695
Medication Adherence in the Real World: Lessons from the Diuretic Comparison Project
Background/Objectives: Antihypertensive treatment is crucial for preventing major adverse cardiovascular events, but suboptimal adherence remains a challenge. Methods: This is a secondary analysis of routine care data from a large pragmatic trial comparing two thiazide diuretics: chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). In the trial, 13,523 older hypertensive patients were randomized from 72 Veterans Affairs medical centers. Medication possession ratio (MPR), reflecting adherence to either study medication (CTD or HCTZ), was used and compared across all randomized patients. Results: The overall median MPR was 95% for all randomized patients and 80% for 6656 individuals who reached 2.4 years for the average follow-up. Lower MPR was observed in Black, separated, urban-living, and comorbid patients. About 30% of the participants (n = 4022) were categorized as non-adherent using a definition of MPR < 80%. Those with baseline systolic blood pressure ≥ 136, recent smoking history, and prior heart failure and Black participants had decreased odds of having an MPR ≥ 80%, while increased odds of reaching that threshold were observed in those who had an eGFR ≥ 60, received ≥3 antihypertensive medications, were married, or resided in rural areas. Conclusions: This analysis provided assessment of real-world medication adherence in a sizable older hypertensive cohort. The proportion of non-adherence found in our analysis was comparable to national trends for US older adults taking blood pressure medications. Identifying sociodemographic characteristics and health conditions associated with non-adherence can help clinicians design targeted interventions for improved adherence to clinically prescribed medications. This is important as hypertension and the older adult population are both expected to grow significantly in the future.
- 12 August 2025
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 14 (16) , 5695
Open AccessMedication Adherence in the Real World: Lessons from the Diuretic Comparison Project
Background/Objectives: Antihypertensive treatment is crucial for preventing major adverse cardiovascular events, but suboptimal adherence remains a challenge. Methods: This is a secondary analysis of routine care data from a large pragmatic trial comparing two thiazide diuretics: chlorthalidone (CTD) and hydrochlorothiazide (HCTZ). In the trial, 13,523 older hypertensive patients were randomized from 72 Veterans Affairs medical centers. Medication possession ratio (MPR), reflecting adherence to either study medication (CTD or HCTZ), was used and compared across all randomized patients. Results: The overall median MPR was 95% for all randomized patients and 80% for 6656 individuals who reached 2.4 years for the average follow-up. Lower MPR was observed in Black, separated, urban-living, and comorbid patients. About 30% of the participants (n = 4022) were categorized as non-adherent using a definition of MPR < 80%. Those with baseline systolic blood pressure ≥ 136, recent smoking history, and prior heart failure and Black participants had decreased odds of having an MPR ≥ 80%, while increased odds of reaching that threshold were observed in those who had an eGFR ≥ 60, received ≥3 antihypertensive medications, were married, or resided in rural areas. Conclusions: This analysis provided assessment of real-world medication adherence in a sizable older hypertensive cohort. The proportion of non-adherence found in our analysis was comparable to national trends for US older adults taking blood pressure medications. Identifying sociodemographic characteristics and health conditions associated with non-adherence can help clinicians design targeted interventions for improved adherence to clinically prescribed medications. This is important as hypertension and the older adult population are both expected to grow significantly in the future.
- Open Access
- 2 December 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (12) , e2449576
Chlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension
Importance: Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.Objective: To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.Design, Setting, and Participants: This prespecified secondary analysis of the Diuretic Comparison Project, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, was conducted between June 1, 2016, and June 1, 2022, through Veterans Affairs facilities nationwide. This analysis extended follow-up to December 31, 2023. Veterans 65 years or older with hypertension who were taking hydrochlorothiazide were included.Intervention: The Diuretic Comparison Project randomized 13 523 participants to continue hydrochlorothiazide or switch to chlorthalidone.Main Outcome and Measures: The main kidney outcome was CKD progression, defined as doubling of serum creatinine level from baseline, a terminal estimated glomerular filtration rate (eGFR) less than 15 mL/min, or dialysis initiation.Results: Analysis included 12 265 participants (90.7%) with a baseline and 1 or more follow-up creatinine measurements (median [IQR] age, 71 [69-75] years; 3.2% female and 96.8% male). The mean (SD) study duration was 3.9 (1.3) years. Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 of 6118 [6.0%] vs 396 of 6147 [6.4%]; hazard ratio [HR], 0.94; 95% CI, 0.81-1.08; P = .37). Similar results were observed when a 40% or greater reduction of eGFR was substituted for doubling of creatinine in the above outcome, as well as any of the components of the primary composite outcome. There was no difference in the incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P = .59) or acute kidney injury requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P = .63) between groups. However, a statistically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9%]; P < .001).Conclusions and Relevance: Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associated with an increased risk for hypokalemia. Given these findings, clinicians should feel confident using either agent for the treatment of hypertension and kidney outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT02185417
- 2 December 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (12) , e2449576
Open AccessChlorthalidone vs Hydrochlorothiazide and Kidney Outcomes in Patients With Hypertension
Importance: Hypertension is a risk factor for the development and progression of chronic kidney disease (CKD). It is unclear whether different thiazide diuretics have a differential impact on kidney outcomes.Objective: To compare kidney outcomes in patients with hypertension taking chlorthalidone and hydrochlorothiazide.Design, Setting, and Participants: This prespecified secondary analysis of the Diuretic Comparison Project, a randomized clinical trial comparing chlorthalidone and hydrochlorothiazide for the treatment of hypertension, was conducted between June 1, 2016, and June 1, 2022, through Veterans Affairs facilities nationwide. This analysis extended follow-up to December 31, 2023. Veterans 65 years or older with hypertension who were taking hydrochlorothiazide were included.Intervention: The Diuretic Comparison Project randomized 13 523 participants to continue hydrochlorothiazide or switch to chlorthalidone.Main Outcome and Measures: The main kidney outcome was CKD progression, defined as doubling of serum creatinine level from baseline, a terminal estimated glomerular filtration rate (eGFR) less than 15 mL/min, or dialysis initiation.Results: Analysis included 12 265 participants (90.7%) with a baseline and 1 or more follow-up creatinine measurements (median [IQR] age, 71 [69-75] years; 3.2% female and 96.8% male). The mean (SD) study duration was 3.9 (1.3) years. Chlorthalidone was not superior to hydrochlorothiazide at preventing kidney outcomes (369 of 6118 [6.0%] vs 396 of 6147 [6.4%]; hazard ratio [HR], 0.94; 95% CI, 0.81-1.08; P = .37). Similar results were observed when a 40% or greater reduction of eGFR was substituted for doubling of creatinine in the above outcome, as well as any of the components of the primary composite outcome. There was no difference in the incidence of CKD (961 of 4520 [21.3%] for chlorthalidone vs 939 of 4518 [20.8%] for hydrochlorothiazide; P = .59) or acute kidney injury requiring hospitalization (391 [6.4%] for chlorthalidone vs 379 [6.2%] for hydrochlorothiazide; P = .63) between groups. However, a statistically significant increased incidence of hypokalemia for chlorthalidone vs hydrochlorothiazide was observed (545 [8.9%] vs 426 [6.9%]; P < .001).Conclusions and Relevance: Chlorthalidone was not superior to hydrochlorothiazide for kidney outcomes but was associated with an increased risk for hypokalemia. Given these findings, clinicians should feel confident using either agent for the treatment of hypertension and kidney outcomes.Trial Registration: ClinicalTrials.gov Identifier: NCT02185417
- Open Access
- 1 May 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (5) , e2411081
Chlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke
Importance: Patients with prior myocardial infarction (MI) or stroke have a greater risk of recurrent cardiovascular (CV) events.Objective: To evaluate the association of chlorthalidone (CTD) vs hydrochlorothiazide (HCTZ) with CV outcomes and noncancer deaths in participants with and without prior MI or stroke.Design, Setting, and Participants: This was a prespecified secondary analysis of the Diuretic Comparison Project (DCP), a pragmatic randomized clinical trial conducted within 72 participating Veterans Affairs health care systems from June 2016 to June 2021, in which patients aged 65 years or older with hypertension taking HCTZ at baseline were randomized to continue HCTZ or switch to CTD at pharmacologically comparable doses. This secondary analysis was performed from January 3, 2023, to February 29, 2024.Exposures: Pharmacologically comparable daily dose of HCTZ or CTD and history of MI or stroke.Main Outcomes and Measures: Outcome ascertainment was performed from randomization to the end of the study. The primary outcome consisted of a composite of stroke, MI, urgent coronary revascularization because of unstable angina, acute heart failure hospitalization, or noncancer death. Additional outcomes included achieved blood pressure and hypokalemia (potassium level P = .01) compared with participants without prior MI or stroke, among whom incidence of the primary outcome was slightly higher in the CTD arm compared with the HCTZ arm (597 of 6023 [9.9%] vs 535 of 6045 [8.9%]; HR, 1.12; 95% CI, 1.00-1.26; P = .054) (P = .01 for interaction). The incidence of a nadir potassium level less than 3.1 mEq/L and hospitalization for hypokalemia differed among those with and without prior MI or stroke when comparing those randomized to CTD vs HCTZ, with a difference only among those without prior MI or stroke (potassium level P = .57]; no prior MI or stroke, 292 of 6023 [4.9%] vs 206 of 6045 [3.4%] [P < .001]; hospitalization for hypokalemia: prior MI or stroke, 14 of 733 [1.9%] vs 16 of 722 [2.2%] [P = .72]; no prior MI or stroke: 84 of 6023 [1.4%] vs 57 of 6045 [0.9%] [P = .02]).Conclusions and Relevance: Results of this secondary analysis of the DCP trial suggest that CTD may be associated with reduced major adverse CV events and noncancer deaths in patients with prior MI or stroke compared with HCTZ.Trial Registration: ClinicalTrials.gov Identifier: NCT02185417
- 1 May 2024
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 7 (5) , e2411081
Open AccessChlorthalidone vs Hydrochlorothiazide for Hypertension Treatment After Myocardial Infarction or Stroke
Importance: Patients with prior myocardial infarction (MI) or stroke have a greater risk of recurrent cardiovascular (CV) events.Objective: To evaluate the association of chlorthalidone (CTD) vs hydrochlorothiazide (HCTZ) with CV outcomes and noncancer deaths in participants with and without prior MI or stroke.Design, Setting, and Participants: This was a prespecified secondary analysis of the Diuretic Comparison Project (DCP), a pragmatic randomized clinical trial conducted within 72 participating Veterans Affairs health care systems from June 2016 to June 2021, in which patients aged 65 years or older with hypertension taking HCTZ at baseline were randomized to continue HCTZ or switch to CTD at pharmacologically comparable doses. This secondary analysis was performed from January 3, 2023, to February 29, 2024.Exposures: Pharmacologically comparable daily dose of HCTZ or CTD and history of MI or stroke.Main Outcomes and Measures: Outcome ascertainment was performed from randomization to the end of the study. The primary outcome consisted of a composite of stroke, MI, urgent coronary revascularization because of unstable angina, acute heart failure hospitalization, or noncancer death. Additional outcomes included achieved blood pressure and hypokalemia (potassium level P = .01) compared with participants without prior MI or stroke, among whom incidence of the primary outcome was slightly higher in the CTD arm compared with the HCTZ arm (597 of 6023 [9.9%] vs 535 of 6045 [8.9%]; HR, 1.12; 95% CI, 1.00-1.26; P = .054) (P = .01 for interaction). The incidence of a nadir potassium level less than 3.1 mEq/L and hospitalization for hypokalemia differed among those with and without prior MI or stroke when comparing those randomized to CTD vs HCTZ, with a difference only among those without prior MI or stroke (potassium level P = .57]; no prior MI or stroke, 292 of 6023 [4.9%] vs 206 of 6045 [3.4%] [P < .001]; hospitalization for hypokalemia: prior MI or stroke, 14 of 733 [1.9%] vs 16 of 722 [2.2%] [P = .72]; no prior MI or stroke: 84 of 6023 [1.4%] vs 57 of 6045 [0.9%] [P = .02]).Conclusions and Relevance: Results of this secondary analysis of the DCP trial suggest that CTD may be associated with reduced major adverse CV events and noncancer deaths in patients with prior MI or stroke compared with HCTZ.Trial Registration: ClinicalTrials.gov Identifier: NCT02185417